<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    		<meta name="keywords" content="Atherosclerosis,ACE inhibitor,Adventitia,Anatomical pathology,Aneurysm,Angina,Angina pectoris,Angiogram,Angioplasty,Anticoagulant,Antioxidant" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="../../../COPYING.html" />
    <title>Atherosclerosis - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../skins/htmldump/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/md5.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/utf8.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/lookup.js"></script>
    <script type="text/javascript" src="../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../raw/MediaWiki%7ECommon.css";
@import "../../../raw/MediaWiki%7EMonobook.css";
@import "../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">Atherosclerosis</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    	    <!-- start content -->
	    <table class="infobox" style="width: 200px; font-size: 95%; text-align: left;">
<caption style="background: lightgrey; font-size: 95%;"><b>Atherosclerosis</b><br />
<i>Classification &amp; external resources</i></caption>
<tr>
<th colspan="2" style="text-align: center; font-size: smaller;">
<div class="center">
<div class="floatnone"><span><a href="../../../e/n/d/Image%7EEndo_dysfunction_Athero.PNG_ea48.html" class="image" title=""><img src="../../../upload/thumb/9/9a/Endo_dysfunction_Athero.PNG/190px-Endo_dysfunction_Athero.PNG" alt="" width="190" height="209" longdesc="../../../e/n/d/Image%7EEndo_dysfunction_Athero.PNG_ea48.html" /></a></span></div>
</div>
</th>
</tr>
<tr style="line-height: 1;">
<td colspan="2" style="text-align:center;"><small>Changes in endothelial dysfunction in atherosclerosis (note text comments about geometry error)</small></td>
</tr>
<tr>
<th><a href="../../../i/c/d/ICD_10d0.html" title="ICD">ICD</a>-<a href="../../../l/i/s/List_of_ICD-10_codes_1183.html" title="List of ICD-10 codes">10</a></th>
<td><a href="../../../i/c/d/ICD-10_Chapter_I_77b5.html" title="ICD-10 Chapter I">I</a><a href="http://www.who.int/classifications/apps/icd/icd10online/?gi70.htm+i70" class="external text" title="http://www.who.int/classifications/apps/icd/icd10online/?gi70.htm+i70" rel="nofollow">70.</a></td>
</tr>
<tr>
<th><a href="../../../i/c/d/ICD_10d0.html" title="ICD">ICD</a>-<a href="../../../l/i/s/List_of_ICD-9_codes_cdaa.html" title="List of ICD-9 codes">9</a></th>
<td><a href="http://www.icd9data.com/getICD9Code.ashx?icd9=440" class="external text" title="http://www.icd9data.com/getICD9Code.ashx?icd9=440" rel="nofollow">440</a></td>
</tr>
<tr>
<th><a href="../../../d/i/s/Diseases_Database_9859.html" title="Diseases Database">DiseasesDB</a></th>
<td><a href="http://www.diseasesdatabase.com/ddb1039.htm" class="external text" title="http://www.diseasesdatabase.com/ddb1039.htm" rel="nofollow">1039</a></td>
</tr>
<tr>
<th><a href="../../../e/m/e/EMedicine_a89c.html" title="EMedicine">eMedicine</a></th>
<td><a href="http://www.emedicine.com/med/topic182.htm" class="external text" title="http://www.emedicine.com/med/topic182.htm" rel="nofollow">med/182</a>&#160;</td>
</tr>
</table>
<p><b>Atherosclerosis</b> is a <a href="../../../d/i/s/Disease.html" title="Disease">disease</a> affecting the <a href="../../../a/r/t/Artery.html" title="Artery">arterial</a> <a href="../../../b/l/o/Blood_vessel.html" title="Blood vessel">blood vessel</a>. It is commonly referred to as a "hardening" or "furring" of the arteries. It is caused by the formation of multiple <a href="../../../a/t/h/Atheroma.html" title="Atheroma">plaques</a> within the arteries.</p>
<p><a href="../../../a/n/a/Anatomical_pathology.html" title="Anatomical pathology">Pathologically</a>, the <b><a href="../../../a/t/h/Atheroma.html" title="Atheroma">atheromatous plaque</a></b> is divided into three distinct components:</p>
<ol>
<li>The <i><a href="../../../a/t/h/Atheroma.html" title="Atheroma">atheroma</a></i> ("lump of porridge", from <i>Athera</i>, <a href="../../../p/o/r/Porridge.html" title="Porridge">porridge</a> in Greek,) is the nodular accumulation of a soft, flaky, yellowish material at the center of large plaques, composed of <a href="../../../m/a/c/Macrophage.html" title="Macrophage">macrophages</a> nearest the <a href="../../../l/u/m/Lumen_%28anatomy%29.html" title="Lumen (anatomy)">lumen</a> of the artery, sometimes with</li>
<li>Underlying areas of <a href="../../../c/h/o/Cholesterol.html" title="Cholesterol">cholesterol</a> crystals, and possibly also</li>
<li>Calcification at the outer base of older/more advanced lesions.</li>
</ol>
<p>The following terms are similar, yet distinct, in both spelling and meaning, and can be easily confused: arteriosclerosis, arteriolosclerosis and atherosclerosis. <b>Arteriosclerosis</b>, is a general term describing any hardening (and loss of elasticity) of medium or large arteries (in Greek, "Arterio" meaning artery and "sclerosis" meaning hardening), <b>arteriolosclerosis</b> is arteriosclerosis mainly affecting the <a href="../../../a/r/t/Arteriole.html" title="Arteriole">arterioles</a> (small arteries), <b>atherosclerosis</b> is a hardening of an artery specifically due to an atheromatous plaque. Therefore, atherosclerosis is a form of arteriosclerosis.</p>
<p><b>Arteriosclerosis</b> ("hardening of the artery") results from a deposition of tough, rigid <a href="../../../c/o/l/Collagen.html" title="Collagen">collagen</a> inside the vessel wall and around the atheroma. This increases the stiffness, decreases the elasticity of the artery wall. <b>Arteriolosclerosis</b> (hardening of small arteries, the <a href="../../../a/r/t/Arteriole.html" title="Arteriole">arterioles</a>) is the result of collagen deposition, but also muscle wall thickening and deposition of protein ("hyaline").</p>
<p><a href="../../../d/y/s/Dystrophic_calcification.html" title="Dystrophic calcification">Calcification</a>, sometimes even <a href="../../../o/s/s/Ossification.html" title="Ossification">ossification</a> (formation of complete bone tissue) occurs within the deepest and oldest layers of the <a href="../../../a/t/h/Atheroma.html" title="Atheroma">sclerosed</a> vessel wall.</p>
<p>Atherosclerosis causes two main problems. First, the <a href="../../../a/t/h/Atheroma.html" title="Atheroma">atheromatous plaques</a>, though long compensated for by artery enlargement, eventually lead to plaque ruptures and <i>stenosis</i> (narrowing) of the artery and, therefore, an insufficient blood supply to the organ it feeds. Alternatively, if the compensating artery enlargement process is excessive, then a net <a href="../../../a/n/e/Aneurysm.html" title="Aneurysm">aneurysm</a> results.</p>
<p>These complications are chronic, slowly progressing and cumulative. Most commonly, soft plaque suddenly <i>ruptures</i> (see <a href="../../../v/u/l/Vulnerable_plaque.html" title="Vulnerable plaque">vulnerable plaque</a>), causing the formation of a thrombus that will rapidly slow or stop blood flow, e.g. 5 minutes, leading to death of the tissues fed by the artery. This catastrophic event is called an <i><a href="../../../i/n/f/Infarction.html" title="Infarction">infarction</a></i>. One of the most common recognized scenarios is called <a href="../../../c/o/r/Coronary_thrombosis.html" title="Coronary thrombosis">coronary thrombosis</a> of a <a href="../../../c/o/r/Coronary_artery.html" title="Coronary artery">coronary artery</a> causing <a href="../../../m/y/o/Myocardial_infarction.html" title="Myocardial infarction">myocardial infarction</a> (a heart attack). Another common scenario in very advanced disease is <i><a href="../../../c/l/a/Claudication.html" title="Claudication">claudication</a></i> from insufficient blood supply to the legs, typically due to a combination of both stenosis and aneurysmal segments narrowed with <a href="../../../t/h/r/Thrombus.html" title="Thrombus">clots</a>. Since atherosclerosis is a body wide process, similar events also occur in the arteries to the brain, intestines, kidneys, legs, etc.</p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Symptoms"><span class="tocnumber">1</span> <span class="toctext">Symptoms</span></a></li>
<li class="toclevel-1"><a href="#Atherogenesis"><span class="tocnumber">2</span> <span class="toctext">Atherogenesis</span></a>
<ul>
<li class="toclevel-2"><a href="#Cellular"><span class="tocnumber">2.1</span> <span class="toctext">Cellular</span></a></li>
<li class="toclevel-2"><a href="#Calcification_and_lipids"><span class="tocnumber">2.2</span> <span class="toctext">Calcification and lipids</span></a></li>
<li class="toclevel-2"><a href="#Visible_features"><span class="tocnumber">2.3</span> <span class="toctext">Visible features</span></a></li>
<li class="toclevel-2"><a href="#Rupture_and_stenosis"><span class="tocnumber">2.4</span> <span class="toctext">Rupture and stenosis</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Diagnosis_of_plaque-related_disease"><span class="tocnumber">3</span> <span class="toctext">Diagnosis of plaque-related disease</span></a></li>
<li class="toclevel-1"><a href="#Physiologic_factors_that_increase_risk"><span class="tocnumber">4</span> <span class="toctext">Physiologic factors that increase risk</span></a></li>
<li class="toclevel-1"><a href="#Treatment"><span class="tocnumber">5</span> <span class="toctext">Treatment</span></a></li>
<li class="toclevel-1"><a href="#Recent_research"><span class="tocnumber">6</span> <span class="toctext">Recent research</span></a></li>
<li class="toclevel-1"><a href="#References"><span class="tocnumber">7</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1"><a href="#External_links"><span class="tocnumber">8</span> <span class="toctext">External links</span></a></li>
<li class="toclevel-1"><a href="#See_also"><span class="tocnumber">9</span> <span class="toctext">See also</span></a></li>
</ul>
</td>
</tr>
</table>
<p><script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script><a name="Symptoms" id="Symptoms"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/h/Atherosclerosis.html" title="Edit section: Symptoms">edit</a>]</span> <span class="mw-headline">Symptoms</span></h2>
<p>Atherosclerosis typically begins in early adolescence, and is usually found in most major <a href="../../../a/r/t/Artery.html" title="Artery">arteries</a>, yet is asymptomatic and not detected by most diagnostic methods during life. Autopsies of healthy young men who died during the Korean and Vietnam Wars showed evidence of the disease. It most commonly becomes seriously symptomatic when interfering with the <a href="../../../c/o/r/Coronary_circulation.html" title="Coronary circulation">coronary circulation</a> supplying the <a href="../../../h/e/a/Heart.html" title="Heart">heart</a> or <a href="../../../c/e/r/Cerebral_circulation.html" title="Cerebral circulation">cerebral circulation</a> supplying the <a href="../../../b/r/a/Brain.html" title="Brain">brain</a>, and is considered the most important underlying cause of <a href="../../../c/e/r/Cerebrovascular_accident.html" title="Cerebrovascular accident">strokes</a>, <a href="../../../m/y/o/Myocardial_infarction.html" title="Myocardial infarction">heart attacks</a>, various <a href="../../../h/e/a/Heart_disease.html" title="Heart disease">heart diseases</a> including <a href="../../../c/o/n/Congestive_heart_failure.html" title="Congestive heart failure">congestive heart failure</a> and most <a href="../../../c/a/r/Cardiovascular_disease.html" title="Cardiovascular disease">cardiovascular diseases</a> in general. Atheroma in arm or more often leg arteries and producing decreased blood flow is called <a href="../../../p/e/r/Peripheral_artery_occlusive_disease.html" title="Peripheral artery occlusive disease">Peripheral artery occlusive disease</a> (PAOD).</p>
<p>According to United States data for the year 2004, for about 65% of men and 47% of women, the first <a href="../../../s/y/m/Symptom.html" title="Symptom">symptom</a> of atherosclerotic <a href="../../../c/a/r/Cardiovascular_disease.html" title="Cardiovascular disease">cardiovascular disease</a> is <a href="../../../m/y/o/Myocardial_infarction.html" title="Myocardial infarction">heart attack</a> or <a href="../../../c/a/r/Cardiac_arrest.html" title="Cardiac arrest">sudden cardiac death</a> (death within one hour of onset of the symptom).</p>
<p>Most artery flow disrupting events occur at locations with less than 50% <a href="../../../l/u/m/Lumen_%28anatomy%29.html" title="Lumen (anatomy)">lumen</a> narrowing (~20% <a href="../../../s/t/e/Stenosis.html" title="Stenosis">stenosis</a> is average. [The reader might reflect that the illustration above, like most illustrations of arterial disease, over emphasizes lumen narrowing as opposed to compensatory external diameter enlargement (at least within smaller, e.g. heart arteries) typical of the atherosclerosis process as it progresses, see Reference 1, Glagov S, below and the <a href="http://jama.ama-assn.org/cgi/reprint/jama;295/13/1556.pdf?ijkey=Md42dlk7z9TzyL8&amp;keytype=finite" class="external text" title="http://jama.ama-assn.org/cgi/reprint/jama;295/13/1556.pdf?ijkey=Md42dlk7z9TzyL8&amp;keytype=finite" rel="nofollow">|ASTEROID</a> trial, the <a href="../../../i/v/u/IVUS_29a6.html" title="IVUS">IVUS</a> photographs on page 8, as examples for a more accurate understanding.] The relative geometry error within the illustration is common to many older illustrations, an error slowly being more commonly recognized within the last decade.</p>
<p><a href="../../../c/a/r/Cardiac_stress_test.html" title="Cardiac stress test">Cardiac stress testing</a>, traditionally the most commonly performed non-invasive testing method for blood flow limitations generally only detects <a href="../../../l/u/m/Lumen_%28anatomy%29.html" title="Lumen (anatomy)">lumen</a> narrowing of ~75% or greater, although some physicians advocate that nuclear stress methods can detect as little as 50%.</p>
<p><a name="Atherogenesis" id="Atherogenesis"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/h/Atherosclerosis.html" title="Edit section: Atherogenesis">edit</a>]</span> <span class="mw-headline">Atherogenesis</span></h2>
<p><i>Atherogenesis</i> is the developmental process of atheromatous plaques. It is characterized by a remodeling of <a href="../../../a/r/t/Artery.html" title="Artery">arteries</a> involving the concomitant accumulation of fatty substances called plaques. One recent theory suggests that for unknown reasons, <a href="../../../l/e/u/Leukocytes.html" title="Leukocytes">leukocytes</a> such as <a href="../../../m/o/n/Monocytes.html" title="Monocytes">monocytes</a> or <a href="../../../b/a/s/Basophils.html" title="Basophils">basophils</a> begin to attack the <a href="../../../e/n/d/Endothelium.html" title="Endothelium">endothelium</a> of the artery lumen in cardiac muscle. The ensuing <a href="../../../i/n/f/Inflammation.html" title="Inflammation">inflammation</a> leads to formation of <i>atheromatous plaques</i> in the arterial intima, a region of the vessel wall located between the <a href="../../../e/n/d/Endothelium.html" title="Endothelium">endothelium</a> and the <a href="../../../t/u/n/Tunica_media.html" title="Tunica media">media</a> and <a href="../../../a/d/v/Adventitia.html" title="Adventitia">adventitia</a>. The bulk of these lesions are made of excess fat, <a href="../../../c/o/l/Collagen.html" title="Collagen">collagen</a>, and <a href="../../../e/l/a/Elastin.html" title="Elastin">elastin</a>. The plaques initially grow without producing any narrowing, <a href="../../../s/t/e/Stenosis.html" title="Stenosis">stenosis</a>, of the artery opening, called the lumen.</p>
<p><a name="Cellular" id="Cellular"></a></p>
<h3><span class="editsection">[<a href="../../../a/t/h/Atherosclerosis.html" title="Edit section: Cellular">edit</a>]</span> <span class="mw-headline">Cellular</span></h3>
<p>The first step of atherogenesis is the development of <a href="../../../f/a/t/Fatty_streak.html" title="Fatty streak">fatty streaks</a>, small subendothelial deposits of lipid. The exact cause for this process is unknown, and fatty streaks may appear and disappear.</p>
<p>LDL in blood plasma poses a risk for <a href="../../../c/a/r/Cardiovascular_disease.html" title="Cardiovascular disease">cardiovascular disease</a> when it invades the <a href="../../../e/n/d/Endothelium.html" title="Endothelium">endothelium</a> and becomes <a href="../../../o/x/i/Oxidize.html" title="Oxidize">oxidized</a>. A complex set of biochemical reactions regulates the oxidation of LDL, chiefly stimulated by presence of <a href="../../../f/r/e/Free_radicals.html" title="Free radicals">free radicals</a> in the <a href="../../../e/n/d/Endothelium.html" title="Endothelium">endothelium</a> or blood vessel lining.</p>
<p>The initial damage to the blood vessel wall results in a "call for help," an <a href="../../../i/n/f/Inflammation.html" title="Inflammation">inflammation</a> response. <a href="../../../m/o/n/Monocyte.html" title="Monocyte">Monocytes</a> (a type of <a href="../../../w/h/i/White_blood_cell.html" title="White blood cell">white blood cell</a>) enter the artery wall from the bloodstream, with platelets adhering to the area of insult. This may be promoted by <a href="../../../r/e/d/Redox_signaling.html" title="Redox signaling">redox signaling</a> induction of factors such as <a href="../../../v/c/a/VCAM-1_e8c8.html" title="VCAM-1">VCAM-1</a>, which recruit circulating monocytes. The <a href="../../../m/o/n/Monocyte.html" title="Monocyte">monocytes</a> differentiate into <a href="../../../m/a/c/Macrophage.html" title="Macrophage">macrophages</a>, which ingest <a href="../../../o/x/i/Oxidize.html" title="Oxidize">oxidized</a> <a href="../../../l/d/l/LDL_0aa2.html" title="LDL">LDL</a>, slowly turning into large "foam cells" – so-described because of their changed appearance resulting from the numerous internal cytoplasmic <a href="../../../v/e/s/Vesicle_%28biology%29.html" title="Vesicle (biology)">vesicles</a> and resulting high <a href="../../../l/i/p/Lipid.html" title="Lipid">lipid</a> content. Under the microscope, the lesion now appears as a fatty streak. Foam cells eventually die, and further propagate the inflammatory process. There is also smooth muscle proliferation and migration from tunica media to intima responding to cytokines secreted by damaged endothelial cells. This would cause the formation of a fibrous capsule covering the fatty streak.</p>
<p><a name="Calcification_and_lipids" id="Calcification_and_lipids"></a></p>
<h3><span class="editsection">[<a href="../../../a/t/h/Atherosclerosis.html" title="Edit section: Calcification and lipids">edit</a>]</span> <span class="mw-headline">Calcification and lipids</span></h3>
<p>Intracellular <a href="../../../c/a/l/Calcification.html" title="Calcification">microcalcifications</a> form within <a href="../../../v/a/s/Vascular_smooth_muscle.html" title="Vascular smooth muscle">vascular smooth muscle</a> cells of the surrounding muscular layer, specifically in the muscle cells adjacent to the atheromas. In time, as cells die, this leads to extracellular calcium deposits between the muscular wall and outer portion of the atheromatous plaques.</p>
<p>Cholesterol is delivered into the vessel wall by cholesterol-containing <a href="../../../l/o/w/Low-density_lipoprotein.html" title="Low-density lipoprotein">low-density lipoprotein</a> (LDL) particles. To attract and stimulate macrophages, the cholesterol must be released from the LDL particles and oxidized, a key step in the ongoing inflammatory process. The process is worsened if there is insufficient <a href="../../../h/i/g/High-density_lipoprotein.html" title="High-density lipoprotein">high-density lipoprotein</a> (HDL), the lipoprotein particle that removes cholesterol from tissues and carries it back to the liver.</p>
<p>The foam cells and platelets encourage the migration and proliferation of <a href="../../../s/m/o/Smooth_muscle.html" title="Smooth muscle">smooth muscle</a> cells, which in turn become replaced by collagen and transform into foam cells themselves. A protective fibrous cap normally forms between the fatty deposits and the artery lining (the <a href="../../../e/n/d/Endothelium.html" title="Endothelium">intima</a>).</p>
<p>These capped fatty deposits (now called <i>atheromas</i>) produce enzymes that cause the artery to enlarge over time. As long as the artery enlarges sufficiently to compensate for the extra thickness of the atheroma, then no narrowing, <a href="../../../s/t/e/Stenosis.html" title="Stenosis">stenosis</a>, of the opening, lumen, occurs. The artery becomes expanded with an egg-shaped cross-section, still with a circular opening. If the enlargement is beyond proportion to the atheroma thickness, then an <a href="../../../a/n/e/Aneurysm.html" title="Aneurysm">aneurysm</a> is created<sup id="_ref-Glagov_0" class="reference"><a href="#_note-Glagov" title="">[1]</a></sup>.</p>
<p><a name="Visible_features" id="Visible_features"></a></p>
<h3><span class="editsection">[<a href="../../../a/t/h/Atherosclerosis.html" title="Edit section: Visible features">edit</a>]</span> <span class="mw-headline">Visible features</span></h3>
<div class="thumb tright">
<div class="thumbinner" style="width:232px;"><a href="../../../a/t/h/Image%7EAtherosclerosis%2C_aorta%2C_gross_pathology_PHIL_846_lores.jpg_4de0.html" class="internal" title="Severe atherosclerosis of the aorta. Autopsy specimen."><img src="../../../upload/shared/thumb/f/f1/Atherosclerosis%2C_aorta%2C_gross_pathology_PHIL_846_lores.jpg/230px-Atherosclerosis%2C_aorta%2C_gross_pathology_PHIL_846_lores.jpg" alt="Severe atherosclerosis of the aorta. Autopsy specimen." width="230" height="358" longdesc="../../../a/t/h/Image%7EAtherosclerosis%2C_aorta%2C_gross_pathology_PHIL_846_lores.jpg_4de0.html" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify" style="float:right"><a href="../../../a/t/h/Image%7EAtherosclerosis%2C_aorta%2C_gross_pathology_PHIL_846_lores.jpg_4de0.html" class="internal" title="Enlarge"><img src="../../../skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Severe atherosclerosis of the <a href="../../../a/o/r/Aorta.html" title="Aorta">aorta</a>. <a href="../../../a/u/t/Autopsy.html" title="Autopsy">Autopsy</a> specimen.</div>
</div>
</div>
<p>Although arteries are not typically studied microscopically, two plaque types can be distinguished<a href="http://www.pathologyatlas.ro/Coronary%20ATS%20Calcification.html" class="external autonumber" title="http://www.pathologyatlas.ro/Coronary%20ATS%20Calcification.html" rel="nofollow">[2]</a>:</p>
<ol>
<li><i>The fibro-lipid (fibro-fatty) plaque</i> is characterized by an accumulation of lipid-laden cells underneath the intima of the arteries, typically without narrowing the lumen due to compensatory expansion of the bounding muscular layer of the artery wall. Beneath the endothelium there is a "fibrous cap" covering the atheromatous "core" of the plaque. The core consists of lipid-laden cells (macrophages and smooth muscle cells) with elevated tissue cholesterol and cholesterol ester content, fibrin, proteoglycans, collagen, elastin and cellular debris. In advanced plaques, the central core of the plaque usually contains extracellular cholesterol deposits (released from dead cells), which form areas of cholesterol crystals with empty, needle-like clefts. At the periphery of the plaque are younger "foamy" cells and capillaries. These plaques usually produce the most damage to the individual when they rupture.</li>
<li><i>The fibrous plaque</i> is also localized under the intima, within the wall of the artery resulting in thickening and expansion of the wall and, sometimes, spotty localized narrowing of the lumen with some atrophy of the muscular layer. The fibrous plaque contains collagen fibres (eosinophilic), precipitates of calcium (hematoxylinophilic) and, rarely, lipid-laden cells.</li>
</ol>
<p>In effect, the muscular portion of the artery wall forms small <a href="../../../a/n/e/Aneurysm.html" title="Aneurysm">aneurysms</a> just large enough to hold the <a href="../../../a/t/h/Atheroma.html" title="Atheroma">atheroma</a> that are present. The muscular portion of artery walls usually remain strong, even after they have remodeled to compensate for the <a href="../../../a/t/h/Atheroma.html" title="Atheroma">atheromatous</a> plaques.</p>
<p>However, <a href="../../../a/t/h/Atheroma.html" title="Atheroma">atheromas</a> within the vessel wall are soft and fragile with little elasticity. Arteries constantly expand and contract with each heartbeat, i.e., the pulse. In addition, the calcification deposits between the outer portion of the atheroma and the muscular wall, as they progress, lead to a loss of elasticity and stiffening of the artery as a whole.</p>
<p>The calcification deposits, after they have become sufficiently advanced, are partially visible on coronary artery <a href="../../../c/o/m/Computed_tomography.html" title="Computed tomography">computed tomography</a> or <a href="../../../e/l/e/Electron_beam_tomography.html" title="Electron beam tomography">electron beam tomography</a> (EBT) as rings of increased radiographic density, forming halos around the outer edges of the atheromatous plaques, within the artery wall. On CT, &gt;130 units on the <a href="../../../h/o/u/Hounsfield_scale.html" title="Hounsfield scale">Hounsfield scale</a> {some argue for 90 units) has been the radiographic density usually accepted as clearly representing tissue calcification within arteries. These deposits demonstrate unequivocal evidence of the disease, relatively advanced, even though the lumen of the artery is often still normal by angiographic or <a href="../../../i/n/t/Intravascular_ultrasound.html" title="Intravascular ultrasound">intravascular ultrasound</a>.</p>
<p><a name="Rupture_and_stenosis" id="Rupture_and_stenosis"></a></p>
<h3><span class="editsection">[<a href="../../../a/t/h/Atherosclerosis.html" title="Edit section: Rupture and stenosis">edit</a>]</span> <span class="mw-headline">Rupture and stenosis</span></h3>
<p>Although the disease process tends to be slowly progressive over decades, it usually remains asymptomatic until an atheroma obstructs the bloodstream in the artery. This is typically by rupture of an atheroma, clotting and fibrous organization of the clot within the lumen, covering the rupture but also producing <a href="../../../s/t/e/Stenosis.html" title="Stenosis">stenosis</a>, or over time and after repeated ruptures, resulting in a persistent, usually localized stenosis. Stenoses can be slowly progressive, while plaque rupture is a sudden event that occurs specifically in atheromas with thinner/weaker fibrous caps that have become "unstable".</p>
<p>Repeated plaque ruptures, ones not resulting in total lumen closure, combined with the clot patch over the rupture and healing response to stabilize the clot, is the process that produces most stenoses over time. The stenotic areas tend to become more stable, despite increased flow velocities at these narrowings. Most major blood-flow-stopping events occur at large plaques, which, prior to their rupture, produced very little if any stenosis.</p>
<p>From clinical trials, 20% is the average stenosis at plaques that subsequently rupture with resulting complete artery closure. Most severe clinical events do not occur at plaques that produce high-grade stenosis. From clinical trials, only 14% of heart attacks occur from artery closure at plaques producing a 75% or greater stenosis prior to the vessel closing.</p>
<p>If the fibrous cap separating a soft atheroma from the bloodstream within the artery ruptures, tissue fragments are exposed and released, and blood enters the atheroma within the wall and sometimes results in a sudden expansion of the atheroma size. Tissue fragments are very clot-promoting, containing <a href="../../../c/o/l/Collagen.html" title="Collagen">collagen</a> and <a href="../../../t/i/s/Tissue_factor.html" title="Tissue factor">tissue factor</a>; they activate <a href="../../../p/l/a/Platelet.html" title="Platelet">platelets</a> and activate the <a href="../../../c/o/a/Coagulation.html" title="Coagulation">system of coagulation</a>. The result is the formation of a <a href="../../../t/h/r/Thrombus.html" title="Thrombus">thrombus</a> (blood clot) overlying the atheroma, which obstructs blood flow acutely. With the obstruction of blood flow, downstream tissues are starved of <a href="../../../o/x/y/Oxygen.html" title="Oxygen">oxygen</a> and nutrients. If this is the <a href="../../../m/y/o/Myocardium.html" title="Myocardium">myocardium</a> (heart muscle), <a href="../../../a/n/g/Angina.html" title="Angina">angina</a> (cardiac chest pain) or <a href="../../../m/y/o/Myocardial_infarction.html" title="Myocardial infarction">myocardial infarction</a> (heart attack) develops.</p>
<p><a name="Diagnosis_of_plaque-related_disease" id="Diagnosis_of_plaque-related_disease"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/h/Atherosclerosis.html" title="Edit section: Diagnosis of plaque-related disease">edit</a>]</span> <span class="mw-headline">Diagnosis of plaque-related disease</span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:182px;"><a href="../../../c/a/l/Image%7ECalcificatio_atherosclerotica.jpg_5f63.html" class="internal" title="Microphotography of arterial wall with calcified (violet colour) atherosclerotic plaque (haematoxillin &amp; eosin stain)"><img src="../../../upload/shared/thumb/4/49/Calcificatio_atherosclerotica.jpg/180px-Calcificatio_atherosclerotica.jpg" alt="Microphotography of arterial wall with calcified (violet colour) atherosclerotic plaque (haematoxillin &amp; eosin stain)" width="180" height="145" longdesc="../../../c/a/l/Image%7ECalcificatio_atherosclerotica.jpg_5f63.html" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify" style="float:right"><a href="../../../c/a/l/Image%7ECalcificatio_atherosclerotica.jpg_5f63.html" class="internal" title="Enlarge"><img src="../../../skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Microphotography of arterial wall with calcified (violet colour) atherosclerotic plaque (haematoxillin &amp; eosin stain)</div>
</div>
</div>
<p>Areas of severe narrowing, <a href="../../../s/t/e/Stenosis.html" title="Stenosis">stenosis</a>, detectable by angiography, and to a lesser extent "<a href="../../../s/t/r/Stress_testing.html" title="Stress testing">stress testing</a>" have long been the focus of human diagnostic techniques for <a href="../../../c/a/r/Cardiovascular_disease.html" title="Cardiovascular disease">cardiovascular disease</a>, in general. However, these methods focus on detecting only severe <a href="../../../s/t/e/Stenosis.html" title="Stenosis">narrowing</a>, not the underlying atherosclerosis disease. As demonstrated by human clinical studies, most severe events occur in locations with heavy plaque, yet little or no lumen <a href="../../../s/t/e/Stenosis.html" title="Stenosis">narrowing</a> present before debilitating events suddenly occur. Plaque rupture can lead to artery lumen occlusion within seconds to minutes, and potential permanent debility and sometimes sudden death.</p>
<p>77% lumen <a href="../../../s/t/e/Stenosis.html" title="Stenosis">stenosis</a> used to be considered by cardiologists as the hallmark of clinically significant disease because it is only at this severity of narrowing of the larger heart arteries that recurring episodes of <a href="../../../a/n/g/Angina.html" title="Angina">angina</a> and detectable abnormalities by <a href="../../../s/t/r/Stress_test.html" title="Stress test">stress testing</a> methods are seen. However, clinical trials have shown that only about 14% of clinically-debilitating events occur at locations with this, or greater severity of <a href="../../../s/t/e/Stenosis.html" title="Stenosis">narrowing</a>. The majority of events occur due to atheroma plaque rupture at areas without <a href="../../../s/t/e/Stenosis.html" title="Stenosis">narrowing</a> sufficient enough to produce any <a href="../../../a/n/g/Angina.html" title="Angina">angina</a> or <a href="../../../s/t/r/Stress_test.html" title="Stress test">stress test</a> abnormalities. Thus, since the later-1990s, greater attention is being focused on the "vulnerable plaque."</p>
<p>Though any artery in the body can be involved, usually only severe <a href="../../../s/t/e/Stenosis.html" title="Stenosis">narrowing</a> or obstruction of some arteries, those that supply more critically-important organs are recognized. Obstruction of arteries supplying the heart muscle result in a <a href="../../../m/y/o/Myocardial_infarction.html" title="Myocardial infarction">heart attack</a>. Obstruction of arteries supplying the brain result in a <a href="../../../s/t/r/Stroke.html" title="Stroke">stroke</a>. These events are life-changing, and often result in irreversible loss of function because lost heart muscle and brain cells do not grow back to any significant extent, typically less than 2%.</p>
<p><a name="Physiologic_factors_that_increase_risk" id="Physiologic_factors_that_increase_risk"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/h/Atherosclerosis.html" title="Edit section: Physiologic factors that increase risk">edit</a>]</span> <span class="mw-headline">Physiologic factors that increase risk</span></h2>
<p>Various anatomic, physiological &amp; behavioral risk factors for atherosclerosis are known. These can be divided into various categories: congenital <i>vs</i> acquired, modifiable or not, classical or non-classical. The points labelled '+' in the following list form the core components of "<a href="../../../m/e/t/Metabolic_syndrome.html" title="Metabolic syndrome">metabolic syndrome</a>":</p>
<ul>
<li><a href="../../../s/e/n/Senescence.html" title="Senescence">Advanced age</a></li>
<li><a href="../../../m/a/l/Male.html" title="Male">Male</a> sex</li>
<li>Having <a href="../../../d/i/a/Diabetes.html" title="Diabetes">Diabetes</a> or <a href="../../../i/m/p/Impaired_glucose_tolerance.html" title="Impaired glucose tolerance">Impaired glucose tolerance</a> (IGT) +</li>
<li><a href="../../../d/y/s/Dyslipidemia.html" title="Dyslipidemia">Dyslipidemia</a> (elevated serum <a href="../../../c/h/o/Cholesterol.html" title="Cholesterol">cholesterol</a> or <a href="../../../t/r/i/Triglyceride.html" title="Triglyceride">triglyceride</a> levels): +
<ul>
<li>High serum concentration of <a href="../../../l/o/w/Low_density_lipoprotein.html" title="Low density lipoprotein">low density lipoprotein</a> (LDL, "bad cholesterol"), <a href="../../../l/i/p/Lipoprotein%28a%29.html" title="Lipoprotein(a)">Lipoprotein(a)</a> (a variant of LDL), and / or <a href="../../../v/e/r/Very_low_density_lipoprotein.html" title="Very low density lipoprotein">very low density lipoprotein</a> (VLDL) particles, i.e. "lipoprotein subclass analysis"</li>
<li>Low serum concentration of functioning <a href="../../../h/i/g/High_density_lipoprotein.html" title="High density lipoprotein">high density lipoprotein</a> (HDL, "good cholesterol") particles, i.e. "lipoprotein subclass analysis"</li>
</ul>
</li>
<li><a href="../../../t/o/b/Tobacco_smoking.html" title="Tobacco smoking">Tobacco smoking</a></li>
<li>Having <a href="../../../h/y/p/Hypertension.html" title="Hypertension">high</a> <a href="../../../b/l/o/Blood_pressure.html" title="Blood pressure">blood pressure</a> +</li>
<li>Being <a href="../../../o/b/e/Obesity.html" title="Obesity">obese</a> (in particular <a href="../../../c/e/n/Central_obesity.html" title="Central obesity">central obesity</a>, also referred to as <i>abdominal</i> or <i>male-type</i> obesity) +</li>
<li>A <a href="../../../s/e/d/Sedentary_lifestyle.html" title="Sedentary lifestyle">sedentary lifestyle</a></li>
<li>Having close relatives who have had some complication of atherosclerosis (eg. <a href="../../../c/o/r/Coronary_heart_disease.html" title="Coronary heart disease">coronary heart disease</a> or <a href="../../../s/t/r/Stroke.html" title="Stroke">stroke</a>)</li>
<li>Elevated serum levels of <a href="../../../h/o/m/Homocysteine.html" title="Homocysteine">homocysteine</a></li>
<li>Elevated serum levels of <a href="../../../u/r/i/Uric_acid.html" title="Uric acid">uric acid</a> (also responsible for gout)</li>
<li>Elevated serum <a href="../../../f/i/b/Fibrinogen.html" title="Fibrinogen">fibrinogen</a> concentrations +</li>
<li>Chronic systemic <a href="../../../i/n/f/Inflammation.html" title="Inflammation">inflammation</a> as reflected by upper normal WBC concentrations, elevated <a href="../../../c/_/r/C_reactive_protein.html" title="C reactive protein">hs-CRP</a> and many other blood chemistry markers, most only research level at present, not clinically done.<sup id="_ref-Bhatt_0" class="reference"><a href="#_note-Bhatt" title="">[2]</a></sup></li>
<li><a href="../../../s/t/r/Stress_%28medicine%29.html" title="Stress (medicine)">Stress</a> or symptoms of <a href="../../../c/l/i/Clinical_depression.html" title="Clinical depression">clinical depression</a></li>
<li><a href="../../../h/y/p/Hypothyroidism.html" title="Hypothyroidism">Hypothyroidism</a> (a slow-acting <a href="../../../t/h/y/Thyroid.html" title="Thyroid">thyroid</a>)</li>
<li>High intake of trans-fats and saturated fats in diet</li>
</ul>
<p><a name="Treatment" id="Treatment"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/h/Atherosclerosis.html" title="Edit section: Treatment">edit</a>]</span> <span class="mw-headline">Treatment</span></h2>
<p>If atherosclerosis leads to symptoms, some symptoms such as <a href="../../../a/n/g/Angina_pectoris.html" title="Angina pectoris">angina pectoris</a> can be treated. Non-pharmaceutical means are usually the first method of treatment, such as cessation of smoking and regular exercise. If these methods do not work, medicines are usually the next step in treating cardiovascular diseases, and with improvements, have increasingly become the most effective method over the long term. However, medicines are criticized for their expense, patented control and occasional undesired effects.</p>
<p><a href="../../../d/y/s/Dyslipidemia.html" title="Dyslipidemia">Lipoprotein imbalances</a>, upper normal and especially elevated blood sugar, i.e. <a href="../../../d/i/a/Diabetes.html" title="Diabetes">diabetes</a>, high blood pressure, <a href="../../../h/o/m/Homocysteine.html" title="Homocysteine">homocysteine</a>, stopping smoking, taking <a href="../../../a/n/t/Anticoagulant.html" title="Anticoagulant">anticoagulants</a> (anti-clotting agents) which target clotting factors, taking omega 3 oils from fatty fish or plant oils such as flax or canola oils, exercising and losing weight are the usual focus of treatments which have proved to be helpful in clinical trials. The target serum cholesterol level is ideally equal or less than 4mmol/L (160 mg/dL) and triglycerides equal or less than 2mmol/L 180 (mg/dL).</p>
<p>In general, the group of medications referred to as statins has seen popularity yet they are not approved in most jurisdictions for treating atherosclerosis. They have relatively few short-term undesirable side-effects and have shown some effect in reducing atherosclerotic disease 'events' in some but not all studies such as <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12479764&amp;dopt=Abstract" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12479764&amp;dopt=Abstract" rel="nofollow">ALLHAT</a>.</p>
<p>The newest statin, <a href="../../../r/o/s/Rosuvastatin.html" title="Rosuvastatin">rosuvastatin</a>, has been the first to demonstrate regression of atherosclerotic plaque within the <a href="../../../c/o/r/Coronary_arteries.html" title="Coronary arteries">coronary arteries</a> by <a href="../../../i/v/u/IVUS_29a6.html" title="IVUS">IVUS</a> evaluation<sup id="_ref-Nissen_0" class="reference"><a href="#_note-Nissen" title="">[3]</a></sup>, see the <i>Effect of Very High-Intensity Statin Therapy</i> reference below. The study was not set up to demonstrate clinical benefit or harm. However, for most people, changing their physiologic behaviors, from the usual high risk to greatly reduced risk, requires a combination of several compounds, taken on a daily basis and indefinitely. More and more human treatment trials have been done and are ongoing which demonstrate improved outcome for those people using more complex and effective treatment regimens which change physiologic behaviour patterns to more closely resemble those humans exhibit in childhood at a time before <a href="../../../f/a/t/Fatty_streaks.html" title="Fatty streaks">fatty streaks</a> begin forming.</p>
<p>Lowering lipoprotein little a, a genetic variant of LDL, can be achieved with large daily doses of vitamin B3, niacin. Niacin also tends to shift LDL particle distribution to larger particle size and improve HDL functioning. Work on increasing HDL particle concentration and function, beyond the niacin effect, perhaps even more important, is slowly advancing. Combinations of <a href="../../../s/t/a/Statin.html" title="Statin">statins</a>, <a href="../../../n/i/a/Niacin.html" title="Niacin">niacin</a>, intestinal cholesterol absorption inhibiting supplements (<a href="../../../e/z/e/Ezetimibe.html" title="Ezetimibe">ezetimibe</a> and others, and to a much lesser extent <a href="../../../f/i/b/Fibrate.html" title="Fibrate">fibrates</a> have been the most successful in changing <a href="../../../d/y/s/Dyslipidemia.html" title="Dyslipidemia">dyslipidemia</a> patterns and but, in the case of inhibitors and fibrates without improving clinical outcomes in secondary prevention. In primary prevention, cholesterol lowering agents have not reduced the mortality rates, for example the AFCAPS/TexCAPS and EXCEL trials and the 2 main trials with atorvastatin, Lipitor, as in the ASCOT and SPARCL studies. Dietary changes to achieve benefit have been more controversial, generally far less effective and less widely adhered to with success.</p>
<p>Evidence has increased that people with <a href="../../../d/i/a/Diabetes.html" title="Diabetes">diabetes</a>, despite not having clinically detectable atherosclotic disease, have more severe debility from atherosclerotic events over time than even non-diabetics who have already suffered atherosclerotic events. Thus <a href="../../../d/i/a/Diabetes.html" title="Diabetes">diabetes</a> has been upgraded to be viewed as an advanced atherosclerotic disease equivalent.</p>
<p>Lowering <a href="../../../h/o/m/Homocysteine.html" title="Homocysteine">homocysteine</a> levels, including within the normal range and dietary supplements of Omega 3 oils, especially those from the muscle of some deep salt water living fish species, also have clinical evidence of significant protective effects as confirmed by 6 <a href="../../../d/o/u/Double_blind.html" title="Double blind">double blind</a> <a href="../../../p/l/a/Placebo.html" title="Placebo">placebo</a> <a href="../../../s/c/i/Scientific_control.html" title="Scientific control">controlled</a> human clinical trials.</p>
<p>Aerobic exercise, weight loss, and dietary changes can also help, but are generally much less effective and often more problematic for many to achieve and continue long term.</p>
<p>Medical treatments often focus predominantly on the symptoms. However, over time, the treatments which focus on decreasing the underlying atherosclerosis processes, as opposed to simply treating the symptoms resulting from the atherosclerosis, have been shown by clinical trials to be more effective.</p>
<p>Other physical treatments, helpful in the short term, include minimally invasive <a href="../../../a/n/g/Angioplasty.html" title="Angioplasty">angioplasty</a> procedures to physically expand narrowed arteries and major invasive surgery, such as <a href="../../../c/o/r/Coronary_artery_bypass_surgery.html" title="Coronary artery bypass surgery">bypass surgery</a>, to create additional blood supply connections which go around the more severely narrowed areas.</p>
<p>High dose supplements of vitamin E or C, with the goal of improving <a href="../../../a/n/t/Antioxidant.html" title="Antioxidant">antioxidant</a> protection, have failed to produce any beneficial trends in human, double blind, clinical research trials. However, these trials have consistently used lower doses than those claimed to be effective and have ignored the short half life of high intakes of <a href="../../../v/i/t/Vitamin_C_bba2.html" title="Vitamin C">vitamin C</a> in the body.</p>
<p>On the other hand, the <a href="../../../s/t/a/Statin.html" title="Statin">statins</a>, and some other medications have been shown to have <a href="../../../a/n/t/Antioxidant.html" title="Antioxidant">antioxidant</a> effects, possibly part of their basis for some of their therapeutic success in reducing cardiac 'events'.</p>
<p>The success of statin drugs in clinical trials is based on some reductions in mortality rates, however never in women or people over the age of 70 <a href="http://www.cmaj.ca/cgi/content/full/173/10/1207-a" class="external text" title="http://www.cmaj.ca/cgi/content/full/173/10/1207-a" rel="nofollow">CMAJ</a>. For example, in 4S, the first large placebo controlled, randomized clinical trial of a statin in people with advanced disease who had already suffered a heart attack, the overall mortality rate reduction for those taking the statin, vs. placebo, was 30%. For the subgroup of people in the trial who had Diabetes Mellitus, the mortality rate reduction between statin and placebo was 54%. 4S was a 5.4 year trial which started in 1989 and was published in 1995 after completion. There were 3 more dead women at trial's end on statin than in the group on placebo drug. The <a href="http://jama.ama-assn.org/cgi/reprint/jama;295/13/1556.pdf?ijkey=Md42dlk7z9TzyL8&amp;keytype=finite" class="external text" title="http://jama.ama-assn.org/cgi/reprint/jama;295/13/1556.pdf?ijkey=Md42dlk7z9TzyL8&amp;keytype=finite" rel="nofollow">|ASTEROID</a> trial, mentioned above and in reference 3, has been the first to show actual disease volume regression (see page 8 of the paper which shows cross-sectional areas of the total heart artery wall at start and 2 years of rosuvastatin 40 mg/day treatment); however, its design was not able to "prove" the mortality reduction issue since it has no placebo group.</p>
<p>In summary, the key to the more effective approaches has been better understanding of the widespread and insidious nature of the disease and to combine multiple different treatment strategies, not rely on just one or a few approaches. Additionally, for those approaches, such as lipoprotein transport behaviors, which have been shown to produce the most success, adopting more aggressive combination treatment strategies has generally produced better results, both before and especially after people are symptomatic. However, treating asymptomatic people remains controversial in the medical community.</p>
<p>Patients at risk for atherosclerosis-related diseases are increasingly being treated <a href="../../../p/r/o/Prophylaxis.html" title="Prophylaxis">prophylactically</a> with low-dose <a href="../../../a/s/p/Aspirin.html" title="Aspirin">aspirin</a> and a <a href="../../../s/t/a/Statin.html" title="Statin">statin</a>. The high incidence of cardiovascular disease led Wald and Law<sup id="_ref-Polypill_0" class="reference"><a href="#_note-Polypill" title="">[4]</a></sup> to propose a <i><a href="../../../p/o/l/Polypill.html" title="Polypill">Polypill</a></i>, a once-daily pill containing these two types of drugs in addition to an <a href="../../../a/c/e/ACE_inhibitor_fd43.html" title="ACE inhibitor">ACE inhibitor</a>, <a href="../../../d/i/u/Diuretic.html" title="Diuretic">diuretic</a> and <a href="../../../b/e/t/Beta_blocker.html" title="Beta blocker">beta blocker</a> and <a href="../../../f/o/l/Folic_acid.html" title="Folic acid">folic acid</a>. They maintain that high uptake by the general population by such a <i>Polypill</i> would reduce cardiovascular mortality by 80%. It must be emphasized however that this is purely theoretical, as the Polypill has never been tested in a clinical trial.</p>
<p><a name="Recent_research" id="Recent_research"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/h/Atherosclerosis.html" title="Edit section: Recent research">edit</a>]</span> <span class="mw-headline">Recent research</span></h2>
<p>Methods to increase <a href="../../../h/i/g/High_density_lipoprotein.html" title="High density lipoprotein">high density lipoprotein</a> (HDL) particle concentrations, which in some animal studies largely reverses and remove atheromas, are being developed and researched. <a href="../../../n/i/a/Niacin.html" title="Niacin">Niacin</a> has HDL raising effects (by 10 - 30%) and showed clinical trial benefit in the Coronary Drug Project, however, the drug <a href="../../../t/o/r/Torcetrapib.html" title="Torcetrapib">torcetrapib</a> most effectively raising HDL (by 60%) also raised deaths by 60% and all studies regarding this drug were halted in December 2006.<a href="http://www.nlm.nih.gov/medlineplus/news/fullstory_42459.html" class="external autonumber" title="http://www.nlm.nih.gov/medlineplus/news/fullstory_42459.html" rel="nofollow">[3]</a></p>
<p>An indication of the role of HDL on atherosclerosis has been with the rare Apo-A1 Milano human genetic variant of this HDL protein. Ongoing work starting in the 1990s may lead to human clinical trials probably by about 2008, on using either synthesized Apo-A1 Milano HDL directly or by gene-transfer methods to pass the ability to synthesize the Apo-A1 Milano HDL protein.</p>
<p>The ASTEROID trial used a high-dose of a powerful statin, <a href="../../../r/o/s/Rosuvastatin.html" title="Rosuvastatin">rosuvastatin</a>, and found plaque (intima + media volume) reduction; see the <i>Effect of Very High-Intensity Statin Therapy</i> reference below. No attempt has yet been made to compare this drug with placebo regarding clinical benefit.</p>
<p>Since about 2002, progress in understanding and developing techniques for modulating immune system function so as to significantly suppress the action of macrophages to drive atherosclerotic plaque progression are being developed with considerable success in reducing plaque development in both mice and rabbits. Plans for human trials, hoped for by about 2008, are in progress. Generally these techniques are termed immunomodulation of atherosclerosis.</p>
<p>Genetic expression and control mechanism research, including (a) the PPAR <a href="../../../p/e/r/Peroxisome_proliferator_activated_receptors.html" title="Peroxisome proliferator activated receptors">peroxisome proliferator activated receptors</a> known to be important in blood sugar and variants of lipoprotein production and function and (b) of the multiple variants of the proteins which form the lipoprotein transport particles, is progressing.</p>
<p>Some controversial research has suggested a link between atherosclerosis and the presence of several different <a href="../../../n/a/n/Nanobacteria.html" title="Nanobacteria">nanobacteria</a> in the arteries, e.g. <a href="../../../c/h/l/Chlamydophila_pneumoniae.html" title="Chlamydophila pneumoniae">Chlamydophila pneumoniae</a>, though trials of current antibiotic treatments known to be usually effective in suppressing growth or killing these bacteria have not been successful in improving outcomes.</p>
<p>The immunomodulation approaches mentioned above, because they deal with innate responses of the host to promote atherosclerosis, have far greater prospects for success.</p>
<p><a name="References" id="References"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/h/Atherosclerosis.html" title="Edit section: References">edit</a>]</span> <span class="mw-headline">References</span></h2>
<ol class="references">
<li id="_note-Glagov"><b><a href="#_ref-Glagov_0" title="">^</a></b> Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. <i><a href="../../../n/_/e/N_Engl_J_Med_e886.html" title="N Engl J Med">N Engl J Med</a></i> 1987;316:131-1375. PMID</li>
<li id="_note-Bhatt"><b><a href="#_ref-Bhatt_0" title="">^</a></b> <a href="http://circ.ahajournals.org/cgi/content/full/circulationaha;106/1/136" class="external text" title="http://circ.ahajournals.org/cgi/content/full/circulationaha;106/1/136" rel="nofollow">Deepak L. Bhatt, MD; Eric J. Topol, MD</a> <i>Need to Test the Arterial Inflammation Hypothesis</i>, 2002, referenced on 4/1/06</li>
<li id="_note-Nissen"><b><a href="#_ref-Nissen_0" title="">^</a></b> <a href="http://jama.ama-assn.org/cgi/reprint/jama;295/13/1556.pdf?ijkey=Md42dlk7z9TzyL8&amp;keytype=finite" class="external autonumber" title="http://jama.ama-assn.org/cgi/reprint/jama;295/13/1556.pdf?ijkey=Md42dlk7z9TzyL8&amp;keytype=finite" rel="nofollow">[1]</a>, "Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis".</li>
<li id="_note-Polypill"><b><a href="#_ref-Polypill_0" title="">^</a></b> Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. <i><a href="../../../b/r/i/British_Medical_Journal_9f3e.html" title="British Medical Journal">BMJ</a></i> 2003;326:1419. PMID.</li>
</ol>
<p>5. Stevens, Karen M.J. Douglas, Athanasios N. Saratzis and George D. Kitas Inflammation and atherosclerosis in rheumatoid arthritis Robert J. Expert Rev. Mol. Med. Vol. 7, Issue 7</p>
<p>6. Mol, A 2002 _The Body Multiple: Ontology in medical practice_ London: Duke University Press</p>
<p><a name="External_links" id="External_links"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/h/Atherosclerosis.html" title="Edit section: External links">edit</a>]</span> <span class="mw-headline">External links</span></h2>
<ul>
<li><a href="http://www.pathologyatlas.ro/Coronary%20ATS.html" class="external text" title="http://www.pathologyatlas.ro/Coronary%20ATS.html" rel="nofollow">Atlas of Pathology</a></li>
<li><a href="http://www.athero.org/" class="external text" title="http://www.athero.org/" rel="nofollow">International Atherosclerosis Society</a></li>
</ul>
<p><a name="See_also" id="See_also"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/h/Atherosclerosis.html" title="Edit section: See also">edit</a>]</span> <span class="mw-headline">See also</span></h2>
<ul>
<li><a href="../../../a/r/t/Artery.html" title="Artery">Artery</a></li>
<li><a href="../../../a/t/h/Atheroma.html" title="Atheroma">Atheroma</a></li>
<li><a href="../../../f/a/t/Fatty_streaks.html" title="Fatty streaks">Fatty streaks</a></li>
<li><a href="../../../h/e/a/Heart.html" title="Heart">Heart</a></li>
<li><a href="../../../c/o/r/Coronary_circulation.html" title="Coronary circulation">Coronary circulation</a></li>
<li><a href="../../../c/o/r/Coronary_catheterization.html" title="Coronary catheterization">Coronary catheterization</a></li>
<li><a href="../../../a/n/g/Angiogram.html" title="Angiogram">Angiogram</a></li>
<li><a href="../../../i/v/u/IVUS_29a6.html" title="IVUS">IVUS</a></li>
<li><a href="../../../a/r/t/Arterial_stiffness.html" title="Arterial stiffness">Arterial stiffness</a></li>
</ul>

<!-- 
Pre-expand include size: 3861 bytes
Post-expand include size: 1821 bytes
Template argument size: 720 bytes
Maximum: 2048000 bytes
-->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org../../../a/t/h/Atherosclerosis.html">http://en.wikipedia.org../../../a/t/h/Atherosclerosis.html</a>"</div>
	    <div id="catlinks"><p class='catlinks'><a href="../../../c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Categories</a>: <span dir='ltr'><a href="../../../c/a/r/Category%7ECardiovascular_diseases_8ae8.html" title="Category:Cardiovascular diseases">Cardiovascular diseases</a></span> | <span dir='ltr'><a href="../../../a/n/g/Category%7EAngiology_2155.html" title="Category:Angiology">Angiology</a></span> | <span dir='ltr'><a href="../../../c/a/r/Category%7ECardiology_c3f5.html" title="Category:Cardiology">Cardiology</a></span></p></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../a/t/h/Atherosclerosis.html">Article</a></li><li id="ca-talk"
	       	       ><a href="../../../a/t/h/Talk%7EAtherosclerosis_22f2.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/Atherosclerosis">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../images/wiki-en.png);"
	    href="../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-Main-page"><a href="../../../index.html">Main page</a></li>
	     	      <li id="n-Contents"><a href="../../../c/o/n/Wikipedia%7EContents_3181.html">Contents</a></li>
	     	      <li id="n-Featured-content"><a href="../../../f/e/a/Wikipedia%7EFeatured_content_24ba.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-About-Wikipedia"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-contact"><a href="../../../c/o/n/Wikipedia%7EContact_us_afd6.html">Contact us</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Fundraising">Make a donation</a></li>
	     	      <li id="n-help"><a href="../../../c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	<div id="p-lang" class="portlet">
	  <h5>In other languages</h5>
	  <div class="pBody">
	    <ul>
	      	      <li>
	      <a href="../../../../cs/a/t/e/Ateroskler%C3%B3za.html">Česky</a>
	      </li>
	      	      <li>
	      <a href="../../../../da/%C3%A5/r/e/%C3%85reforkalkning.html">Dansk</a>
	      </li>
	      	      <li>
	      <a href="../../../../de/a/r/t/Arteriosklerose.html">Deutsch</a>
	      </li>
	      	      <li>
	      <a href="../../../../es/a/t/e/Aterosclerosis.html">Español</a>
	      </li>
	      	      <li>
	      <a href="../../../../ko/%EB%8F%99/%EB%A7%A5/%EA%B2%BD/%EB%8F%99%EB%A7%A5%EA%B2%BD%ED%99%94.html">한국어</a>
	      </li>
	      	      <li>
	      <a href="../../../../it/a/t/e/Aterosclerosi.html">Italiano</a>
	      </li>
	      	      <li>
	      <a href="../../../../he/%D7%98/%D7%A8/%D7%A9/%D7%98%D7%A8%D7%A9%D7%AA_%D7%A2%D7%95%D7%A8%D7%A7%D7%99%D7%9D.html">עברית</a>
	      </li>
	      	      <li>
	      <a href="../../../../nl/a/t/h/Atheromatose.html">Nederlands</a>
	      </li>
	      	      <li>
	      <a href="../../../../ja/%E5%8B%95/%E8%84%88/%E7%A1%AC/%E5%8B%95%E8%84%88%E7%A1%AC%E5%8C%96%E7%97%87.html">日本語</a>
	      </li>
	      	      <li>
	      <a href="../../../../pl/m/i/a/Mia%C5%BCd%C5%BCyca.html">Polski</a>
	      </li>
	      	      <li>
	      <a href="../../../../pt/a/t/e/Aterosclerose.html">Português</a>
	      </li>
	      	      <li>
	      <a href="../../../../fi/a/t/e/Ateroskleroosi.html">Suomi</a>
	      </li>
	      	      <li>
	      <a href="../../../../sv/%C3%A5/d/e/%C3%85derf%C3%B6rkalkning.html">Svenska</a>
	      </li>
	      	      <li>
	      <a href="../../../../tr/a/t/e/Ateroskleroz.html">Türkçe</a>
	      </li>
	      	      <li>
	      <a href="../../../../zh/%E5%8A%A8/%E8%84%89/%E7%A1%AC/%E5%8A%A8%E8%84%89%E7%A1%AC%E5%8C%96.html">中文</a>
	      </li>
	      	    </ul>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 20:09, 2 April 2007 by Anonymous user(s) of Wikipedia. Based on work by Wikipedia user(s) <a href="../../../d/a/v/User%7EDavid.Throop_ff18.html" title="User:David.Throop">David.Throop</a>, <a href="../../../l/u/i/User%7ELuisfilipemiguel_69ee.html" title="User:Luisfilipemiguel">Luisfilipemiguel</a>, <a href="../../../w/_/g/User%7EW_guice_dd47.html" title="User:W guice">W guice</a>, <a href="../../../p/i/g/User%7EPigslookfunny_af00.html" title="User:Pigslookfunny">Pigslookfunny</a>, <a href="../../../c/m/d/User%7ECmdrObot_0605.html" title="User:CmdrObot">CmdrObot</a>, <a href="../../../d/i/e/User%7EDieter_Simon_f22e.html" title="User:Dieter Simon">Dieter Simon</a>, <a href="../../../d/e/n/User%7EDennyColt_9f74.html" title="User:DennyColt">DennyColt</a>, <a href="../../../s/q/u/User%7ESquids_and_Chips_bd06.html" title="User:Squids and Chips">Squids and Chips</a>, <a href="../../../f/e/l/User%7EFelisLeo_2ac7.html" title="User:FelisLeo">FelisLeo</a>, <a href="../../../p/l/a/User%7EPlanetneutral_0d3a.html" title="User:Planetneutral">Planetneutral</a>, <a href="../../../d/v/d/User%7EDVD_R_W_e2d2.html" title="User:DVD R W">DVD R W</a>, <a href="../../../s/c/o/User%7EScohoust_8280.html" title="User:Scohoust">Scohoust</a>, N1ckels, <a href="../../../c/a/n/User%7ECan%27t_sleep%2C_clown_will_eat_me_7058.html" title="User:Can't sleep, clown will eat me">Can't sleep, clown will eat me</a>, Ntmatter, <a href="../../../t/h/e/User%7ETheProject_f8b7.html" title="User:TheProject">TheProject</a>, Boyd Steere, <a href="../../../c/h/o/User%7EChobot_0dce.html" title="User:Chobot">Chobot</a>, <a href="../../../f/a/r/User%7EFarosdaughter_ce1a.html" title="User:Farosdaughter">Farosdaughter</a>, Nucleophilic, <a href="../../../c/o/r/User%7ECorti_28b4.html" title="User:Corti">Corti</a>, <a href="../../../a/n/t/User%7EAntiVandalBot_aa84.html" title="User:AntiVandalBot">AntiVandalBot</a>, <a href="../../../e/d/d/User%7EEddievos_1071.html" title="User:Eddievos">Eddievos</a>, <a href="../../../x/2/0/User%7EX201_1eb7.html" title="User:X201">X201</a>, <a href="../../../m/e/r/User%7EMER-C_4926.html" title="User:MER-C">MER-C</a>, <a href="../../../d/a/v/User%7EDavidruben_76a6.html" title="User:Davidruben">Davidruben</a>, Danjeffers, <a href="../../../k/u/r/User%7EKuru_b024.html" title="User:Kuru">Kuru</a>, <a href="../../../m/a/l/User%7EMAlvis_975b.html" title="User:MAlvis">MAlvis</a>, <a href="../../../a/r/c/User%7EArcadian_5c4b.html" title="User:Arcadian">Arcadian</a>, <a href="../../../s/t/b/User%7ESTBot_bbca.html" title="User:STBot">STBot</a>, <a href="../../../h/e/x/User%7EHexdump_327e.html" title="User:Hexdump">Hexdump</a>, <a href="../../../f/i/n/User%7EFinavon_5d04.html" title="User:Finavon">Finavon</a>, <a href="../../../l/g/h/User%7ELgh_81a0.html" title="User:Lgh">Lgh</a>, <a href="../../../h/a/h/User%7EHahbie_b23b.html" title="User:Hahbie">Hahbie</a>, <a href="../../../b/e/m/User%7EBemoeial_caf3.html" title="User:Bemoeial">Bemoeial</a>, Vaultdoor, <a href="../../../j/a/r/User%7EJarfingle_2eaa.html" title="User:Jarfingle">Jarfingle</a>, Quentar, <a href="../../../n/e/p/User%7ENephron_555e.html" title="User:Nephron">Nephron</a>, <a href="../../../j/o/e/User%7EJoehall45_dbc4.html" title="User:Joehall45">Joehall45</a>, Elijahaparker, <a href="../../../j/a/m/User%7EJames_McNally_d8fa.html" title="User:James McNally">James McNally</a>, <a href="../../../g/r/a/User%7EGrahams_Child_31b0.html" title="User:Grahams Child">Grahams Child</a>, <a href="../../../p/o/l/User%7EPol098_88b3.html" title="User:Pol098">Pol098</a>, <a href="../../../k/p/j/User%7EKpjas_9cb5.html" title="User:Kpjas">Kpjas</a>, <a href="../../../e/l/r/User%7EElroch_ff10.html" title="User:Elroch">Elroch</a>, <a href="../../../f/o/l/User%7EFolajimi_dee8.html" title="User:Folajimi">Folajimi</a>, <a href="../../../j/f/d/User%7EJfdwolff_9ea6.html" title="User:Jfdwolff">Jfdwolff</a>, <a href="../../../f/r/e/User%7EFrenchman113_bb46.html" title="User:Frenchman113">Frenchman113</a>, <a href="../../../j/o/n/User%7EJon_Cates_a6ea.html" title="User:Jon Cates">Jon Cates</a>, <a href="../../../s/h/a/User%7EShanel_222a.html" title="User:Shanel">Shanel</a>, <a href="../../../s/e/r/User%7ESergio.ballestrero_cf6c.html" title="User:Sergio.ballestrero">Sergio.ballestrero</a>, <a href="../../../v/e/c/User%7EVectro_bf83.html" title="User:Vectro">Vectro</a>, The1anton, <a href="../../../p/i/l/User%7EPilotguy_59e8.html" title="User:Pilotguy">Pilotguy</a>, <a href="../../../a/n/l/User%7EAnlace_5bdb.html" title="User:Anlace">Anlace</a>, <a href="../../../g/a/b/User%7EGabbe_a391.html" title="User:Gabbe">Gabbe</a>, <a href="../../../w/e/t/User%7EWetBandit_a211.html" title="User:WetBandit">WetBandit</a>, <a href="../../../j/o/s/User%7EJoshuagross_9d55.html" title="User:Joshuagross">Joshuagross</a>, <a href="../../../f/d/p/User%7EFdp_ff59.html" title="User:Fdp">Fdp</a>, <a href="../../../s/a/n/User%7ESannse_0094.html" title="User:Sannse">Sannse</a>, <a href="../../../e/m/m/User%7EEmmanuelm_7433.html" title="User:Emmanuelm">Emmanuelm</a>, <a href="../../../m/d/a/User%7EMdawg89_eebd.html" title="User:Mdawg89">Mdawg89</a>, <a href="../../../e/k/i/User%7EEkirth_411d.html" title="User:Ekirth">Ekirth</a>, <a href="../../../d/a/b/User%7EDabMachine_5d4b.html" title="User:DabMachine">DabMachine</a>, <a href="../../../s/c/e/User%7ESceptre_44d8.html" title="User:Sceptre">Sceptre</a>, <a href="../../../c/a/c/User%7ECactus.man_4fe2.html" title="User:Cactus.man">Cactus.man</a>, <a href="../../../s/e/r/User%7ESerrano_aeab.html" title="User:Serrano">Serrano</a>, Paul33, <a href="../../../k/a/t/User%7EKatpatuka_8484.html" title="User:Katpatuka">Katpatuka</a>, <a href="../../../s/m/t/User%7ESmthManly_78cd.html" title="User:SmthManly">SmthManly</a>, <a href="../../../b/l/u/User%7EBluebot_e595.html" title="User:Bluebot">Bluebot</a>, <a href="../../../k/u/m/User%7EKummi_b4e9.html" title="User:Kummi">Kummi</a>, <a href="../../../a/g/t/User%7EAGToth_b1b9.html" title="User:AGToth">AGToth</a>, <a href="../../../n/a/t/User%7ENatalinasmpf_1971.html" title="User:Natalinasmpf">Natalinasmpf</a>, <a href="../../../s/k/a/User%7ESkagedal_c3c6.html" title="User:Skagedal">Skagedal</a>, Iconoclast2, Kashmircat, <a href="../../../f/o/r/User%7EForbsey_d5ce.html" title="User:Forbsey">Forbsey</a>, <a href="../../../c/b/d/User%7ECBDunkerson_e7cf.html" title="User:CBDunkerson">CBDunkerson</a>, <a href="../../../w/i/n/User%7EWingchi_3640.html" title="User:Wingchi">Wingchi</a>, <a href="../../../c/o/m/User%7ECommander_Keane_bot_0a32.html" title="User:Commander Keane bot">Commander Keane bot</a>, <a href="../../../t/o/c/User%7ETocotrienols_5134.html" title="User:Tocotrienols">Tocotrienols</a>, <a href="../../../d/o/o/User%7EDoops_385d.html" title="User:Doops">Doops</a>, <a href="../../../w/o/u/User%7EWouterstomp_b006.html" title="User:Wouterstomp">Wouterstomp</a>, <a href="../../../v/a/d/User%7EVadim_Makarov_cde9.html" title="User:Vadim Makarov">Vadim Makarov</a>, <a href="../../../k/r/u/User%7EKrun_8d95.html" title="User:Krun">Krun</a>, <a href="../../../c/h/e/User%7EChelsea7_30fb.html" title="User:Chelsea7">Chelsea7</a>, <a href="../../../j/a/r/User%7EJared81_0ab9.html" title="User:Jared81">Jared81</a>, <a href="../../../e/r/i/User%7EEric_Kvaalen_2860.html" title="User:Eric Kvaalen">Eric Kvaalen</a>, <a href="../../../m/a/r/User%7EMargosbot_a231.html" title="User:Margosbot">Margosbot</a>, <a href="../../../m/d/a/User%7EMdanciu_1392.html" title="User:Mdanciu">Mdanciu</a>, <a href="../../../l/y/l/User%7ELylum_8544.html" title="User:Lylum">Lylum</a>, <a href="../../../e/r/a/User%7EEras-mus_f9f9.html" title="User:Eras-mus">Eras-mus</a>, <a href="../../../p/e/t/User%7EPetersam_7af3.html" title="User:Petersam">Petersam</a>, <a href="../../../b/r/i/User%7EBrim_2417.html" title="User:Brim">Brim</a>, <a href="../../../r/s/a/User%7ERsabbatini_b527.html" title="User:Rsabbatini">Rsabbatini</a>, <a href="../../../p/j/f/User%7EPjf_0394.html" title="User:Pjf">Pjf</a>, <a href="../../../s/a/m/User%7ESam_Hocevar_dccf.html" title="User:Sam Hocevar">Sam Hocevar</a>, <a href="../../../i/d/a/User%7EIdahoEv_a81d.html" title="User:IdahoEv">IdahoEv</a>, <a href="../../../j/u/m/User%7EJumbuck_a815.html" title="User:Jumbuck">Jumbuck</a>, <a href="../../../n/u/n/User%7ENunh-huh_d05a.html" title="User:Nunh-huh">Nunh-huh</a>, <a href="../../../t/a/r/User%7ETarek_3966.html" title="User:Tarek">Tarek</a>, <a href="../../../r/o/b/User%7ERobbot_3bd9.html" title="User:Robbot">Robbot</a>, <a href="../../../m/i/n/User%7EMindspillage_87a5.html" title="User:Mindspillage">Mindspillage</a>, <a href="../../../p/n/e/User%7EPne_05d6.html" title="User:Pne">Pne</a>, <a href="../../../e/d/h/User%7EEdH_fee0.html" title="User:EdH">EdH</a>, <a href="../../../f/f/i/User%7EFfirehorse_654d.html" title="User:Ffirehorse">Ffirehorse</a>, <a href="../../../p/f/h/User%7EPFHLai_0319.html" title="User:PFHLai">PFHLai</a>, <a href="../../../s/a/r/User%7ESarge_Baldy_6bdd.html" title="User:Sarge Baldy">Sarge Baldy</a>, <a href="../../../h/a/l/User%7EHalibutt_9a46.html" title="User:Halibutt">Halibutt</a>, <a href="../../../l/a/n/User%7ELancevortex_a6a9.html" title="User:Lancevortex">Lancevortex</a>, <a href="../../../m/a/x/User%7EMaximus_Rex_f7db.html" title="User:Maximus Rex">Maximus Rex</a>, <a href="../../../s/i/m/User%7ESimonP_1010.html" title="User:SimonP">SimonP</a>, <a href="../../../m/r/-/User%7EMr-Natural-Health_8c72.html" title="User:Mr-Natural-Health">Mr-Natural-Health</a>, <a href="../../../k/d/4/User%7EKd4ttc_9614.html" title="User:Kd4ttc">Kd4ttc</a>, <a href="../../../j/w/r/User%7EJwrosenzweig_7ca4.html" title="User:Jwrosenzweig">Jwrosenzweig</a>, <a href="../../../a/n/g/User%7EAngela_56ea.html" title="User:Angela">Angela</a>, <a href="../../../z/i/g/User%7EZigger_b33b.html" title="User:Zigger">Zigger</a>, <a href="../../../g/l/e/User%7EGlenn_a98b.html" title="User:Glenn">Glenn</a>, Stek, <a href="../../../e/v/a/User%7EEvanherk_f0e1.html" title="User:Evanherk">Evanherk</a>, <a href="../../../k/i/m/User%7EKimiko_090c.html" title="User:Kimiko">Kimiko</a>, <a href="../../../a/l/e/User%7EAlex.tan_6c56.html" title="User:Alex.tan">Alex.tan</a>, <a href="../../../t/r/i/User%7ETristanb_d761.html" title="User:Tristanb">Tristanb</a>, <a href="../../../m/i/l/User%7EMilkfish_be4e.html" title="User:Milkfish">Milkfish</a>, <a href="../../../s/t/a/User%7EStatkit1_6587.html" title="User:Statkit1">Statkit1</a>, <a href="../../../m/y/r/User%7EMyRedDice_bcb5.html" title="User:MyRedDice">MyRedDice</a> and <a href="../../../a/x/e/User%7EAxelBoldt_4306.html" title="User:AxelBoldt">AxelBoldt</a>.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="../../../t/e/x/Wikipedia%7EText_of_the_GNU_Free_Documentation_License_702a.html" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="../../../c/o/p/Wikipedia%7ECopyrights_92c4.html" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a US-registered <a class='internal' href="../../../5/0/1/501%28c%29.html#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="../../../n/o/n/Non-profit_organization.html" title="Non-profit organization">nonprofit</a> <a href="../../../c/h/a/Charitable_organization.html" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
